TVRD Tvardi Therapeutics, Inc.
$0.84▼ -10.41%
Healthcare
Other
Volume 139.0K
Avg Volume (10D) 117.1K
Key Metrics & Fundamentals
Market Cap
$11.23M
P/E Ratio
–
Div Yield
0.00%
52W Range
0.84 - 5.69
% vs 50 MA
-42.33%
% vs 200 MA
-70.28%
RSI-14
26.7
MACD Histogram
+0.0100
Beta (1Y vs SPY)
1.34
Free Cash Flow
-$9.23M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$6.61M
COGS
–
Operating Exp
$6.63M
Operating Income
-$6.63M
EBIT
-$6.63M
Pretax Income
-$6.46M
Net Income
-$6.46M
EPS (Diluted)
-0.69
Price & Volume History
Loading chart…
Recent News
Chardan Initiates Tvardi Therapeutics at Buy With $8 Price Target
MT Newswires · Oct 20, 2026 6:54 AM ET
Tvardi Therapeutics to Participate in Chardan’s 10th Annual Healthcare Conference
GlobeNewswire · Oct 14, 2026 8:00 AM ET
New Preclinical Data Further Support Potential for Tvardi’s STAT3 Inhibitors in Ulcerative Colitis (UC)
GlobeNewswire · Sep 24, 2026 8:00 AM ET
Tvardi Therapeutics to Participate in Upcoming Investor Events
GlobeNewswire · Aug 26, 2026 8:00 AM ET
Tvardi: Q2 Earnings Snapshot
Associated Press · Aug 14, 2026 7:07 AM ET
Tvardi Therapeutics Announces Second Quarter 2026 Results and Provides Business Update
GlobeNewswire · Aug 14, 2026 7:00 AM ET
Tvardi Therapeutics to Host KOL Webinar on the Clinical Potential of TTI-109 in Ulcerative Colitis (UC) and the Evolving Treatment Landscape, on August 19, 2026
GlobeNewswire · Aug 12, 2026 8:00 AM ET
Tvardi Therapeutics Selects Ulcerative Colitis as Initial Indication for TTI-109
GlobeNewswire · Jul 30, 2026 7:30 AM ET
Financial Overview - Income Statement
Quarterly
Mar 2025
See TVRD's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.